Gastric Cancer
A Multicenter, Randomized, Open-Label, Phase 3 Trial of Trastuzumab Deruxtecan(Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab versus Chemotherapy PlusTrastuzumab Plus or Minus Pembrolizumab as First-line Treatment in Participants withUnresectable, Locally Advanced or Metastatic HER2-positive Gastric or GastroesophagealJunction (GEJ) Cancer (DESTINY-Gastric05)
- Details
ClinicalTrials.gov ID:
NCT06731478
Diagnosis Type:
NA
USOR Number:
- Address
,
P: